Literature DB >> 12218781

Phenotypical and functional characterization of clinical grade dendritic cells.

I Jolanda M de Vries1, Andreas A O Eggert, Nicole M Scharenborg, Joost L M Vissers, W Joost Lesterhuis, Otto C Boerman, Cornelis J A Punt, Gosse J Adema, Carl G Figdor.   

Abstract

Dendritic cells (DC) are the professional antigen presenting cells of the immune system. Therefore, several clinical studies have been initiated in which tumor antigen-loaded DC are used as a vaccine to boost an immune response against malignant tumors in patients with cancer. A prerequisite for DC used in these vaccination studies is not only that they are grown under "Good Manufacturing Practice" but equally important that they retain their functional properties. In an extensive study, various conditions were tested to optimize the maturation and yield of DC grown for clinical use. DC grown in XVIVO-15 medium supplemented with 5% HS yielded the best results, morphologically and phenotypically. Mature DC expressed significant amounts of mature DC markers (CD83) and the costimulatory molecules CD80 and CD86. It was shown that mature and immature DC can be frozen and retain their phenotype and function after thawing. These clinical grade DC secreted high levels of the chemokines dendritic cell chemokine 1 (DC-CK1), interleukin-8 (IL-8), macrophage-derived chemokine (MDC), and thymus and activation-regulated chemokine (TARC). This implicates that these DC can attract naïve T and B cells as well as natural killer cells and memory T cells. Finally, to test their migratory capacity in vivo, (111)In-labeled DC were injected into tumor-free lymph nodes of patients with melanoma. Autoradiographic analysis of the dissected lymph nodes indicated that these DC could migrate into the T cell area of adjacent lymph nodes. In conclusion, a culture procedure was established to generate large numbers of monocyte-derived immature and mature DC that retain their morphologic, phenotypic, and functional characteristics in vitro and can be visualized in situ.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218781     DOI: 10.1097/00002371-200209000-00007

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  38 in total

1.  Production of functional dendritic cells from menstrual blood--a new dendritic cell source for immune therapy.

Authors:  Pham Van Phuc; Dang Hoang Lam; Vu Bich Ngoc; Duong Thi Thu; Nguyen Thi Minh Nguyet; Phan Kim Ngoc
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-03-18       Impact factor: 2.416

2.  Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.

Authors:  A Escobar; M López; A Serrano; M Ramirez; C Pérez; A Aguirre; R González; J Alfaro; M Larrondo; M Fodor; C Ferrada; F Salazar-Onfray
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

3.  Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation.

Authors:  Christian Büll; Estel Collado-Camps; Esther D Kers-Rebel; Torben Heise; Jonas N Søndergaard; Martijn H den Brok; Barbara M Schulte; Thomas J Boltje; Gosse J Adema
Journal:  Immunol Cell Biol       Date:  2016-11-22       Impact factor: 5.126

4.  Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

Authors:  W Joost Lesterhuis; Cornelis J A Punt; Stanleyson V Hato; Dagmar Eleveld-Trancikova; Bastiaan J H Jansen; Stefan Nierkens; Gerty Schreibelt; Annemiek de Boer; Carla M L Van Herpen; Johannes H Kaanders; Johan H J M van Krieken; Gosse J Adema; Carl G Figdor; I Jolanda M de Vries
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

Review 5.  Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes.

Authors:  Evemie Schutyser; Ann Richmond; Jo Van Damme
Journal:  J Leukoc Biol       Date:  2005-03-22       Impact factor: 4.962

6.  Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2.

Authors:  Oliver Grauer; Peter Pöschl; Annette Lohmeier; Gosse J Adema; Ulrich Bogdahn
Journal:  J Neurooncol       Date:  2006-11-15       Impact factor: 4.130

7.  Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer.

Authors:  Irina Obleukhova; Nataliya Kiryishina; Svetlana Falaleeva; Julia Lopatnikova; Vasiliy Kurilin; Vadim Kozlov; Aleksander Vitsin; Andrey Cherkasov; Ekaterina Kulikova; Sergey Sennikov
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

8.  Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy.

Authors:  Andrew N Cornforth; Gregory J Lee; Abner W Fowler; Denysha J Carbonell; Robert O Dillman
Journal:  J Clin Immunol       Date:  2009-05-07       Impact factor: 8.317

9.  Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy.

Authors:  Rachel Lubong Sabado; Elizabeth Miller; Meredith Spadaccia; Isabelita Vengco; Farah Hasan; Nina Bhardwaj
Journal:  J Vis Exp       Date:  2013-08-01       Impact factor: 1.355

10.  Podosomes of dendritic cells facilitate antigen sampling.

Authors:  Maksim Baranov; Martin Ter Beest; Inge Reinieren-Beeren; Alessandra Cambi; Carl G Figdor; Geert van den Bogaart
Journal:  J Cell Sci       Date:  2014-01-14       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.